We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-15.85%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$591M
AUM Growth
-$79.2M
Cap. Flow
+$97.6M
Cap. Flow %
16.5%
Top 10 Hldgs %
98.44%
Holding
11
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$107M
2
APTX
Aptinyx Inc. Common Stock
APTX
+$10.9M
3
DVAX
Dynavax Technologies
DVAX
+$1.29M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$21.6M

Sector Composition

Rank Sector Weight
1 Healthcare 85.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$197M 33.25%
7,281,307
– –
ARQT icon
2
Arcutis Biotherapeutics
ARQT
$3.26B
$119M 20.05%
+3,979,292
New +$107M
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$75M 12.68%
4,080,237
– –
CNST
4
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$69.3M 11.71%
2,203,529
-620,000
-22% -$21.6M
DVAX
5
DELISTED
Dynavax Technologies
DVAX
$30.8M 5.21%
8,730,707
+278,472
+3% +$1.29M
REPL icon
6
Replimune Group
REPL
$1.15B
$28.3M 4.79%
2,838,968
– –
SVRA icon
7
Savara
SVRA
$1.17B
$23M 3.89%
5,128,593
– –
XFOR icon
8
X4 Pharmaceuticals
XFOR
$421M
$16.5M 2.79%
54,950
– –
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.1M 2.04%
1,485,684
– –
APTX
10
DELISTED
Aptinyx Inc. Common Stock
APTX
$12M 2.03%
5,558,425
+3,333,333
+150% +$10.9M
SLDB icon
11
Solid Biosciences
SLDB
$918M
$9.25M 1.56%
258,078
– –

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q1 2020 Portfolio in Review

As of Q1 2020, Bain Capital Life Sciences Investors held 11 positions worth $591M, down 12% from $671M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Bain Capital Life Sciences Investors deployed $97.6M of net new capital in Q1 2020, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Arcutis Biotherapeutics: 3,979,292 shares worth $119M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $21.6M trimmed.

  • Bain Capital Life Sciences Investors's largest Q1 2020 buy was Arcutis Biotherapeutics: 3,979,292 shares worth $119M.
  • Bain Capital Life Sciences Investors added most to Aptinyx Inc. Common Stock in Q1 2020, an estimated $10.9M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2020 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $21.6M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 98% of its $591M portfolio in Q1 2020.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 0 in Q1 2020.
  • Bain Capital Life Sciences Investors's portfolio value fell 12% quarter-over-quarter to $591M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2020, filed 15 May 2020.